Radiopharmaceutical production in clinic Doctor Manduul (Mongolia)(TEIN Lecture Series 2022 2nd)

Value of the Information & Strength of the Argument

The presentation provides valuable practical insights into establishing a radiopharmaceutical production facility in a resource-limited setting. The speakers share specific data on production yields, quality control tests, and operational challenges, which is useful for other centers planning similar projects. The argumentation is based on direct experience, making it credible. However, the presentation is largely descriptive and lacks in-depth analysis of alternative approaches or comparative data from other facilities. The discussion of challenges is honest but could benefit from more detailed solutions.

Scientific Rigor, Source Quality, Title Accuracy

The presentation is based on the speakers’ direct experience, which lends it authenticity. They reference international standards (USP, IAEA, GMP) and acknowledge the role of international experts (e.g., from KIRAMS). However, no specific scientific literature is cited, and the data presented are from a single center. The title accurately reflects the content, which is a case study of radiopharmaceutical production in a clinical setting. The presentation is well-structured and informative, though it would benefit from more rigorous referencing.

The title accurately reflects the content, which focuses on the clinical production of radiopharmaceuticals in Mongolia.

7/10

The presentation is based on direct experience from a clinical cyclotron facility, with specific data on production yields and quality control. However, it is a single-center experience with limited peer review, and some details are presented without in-depth technical explanation.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction of Dr. Manduul and the topic of radiopharmaceutical production.
• 05:00Overview of nuclear medicine services in Mongolia and the need for PET/CT.
• 10:00Timeline of the project from 2012 to 2020, including equipment installation.
• 15:00First production of F-18 FDG on November 5, 2020, with a chemical yield of 62%.
• 20:00Quality control tests performed according to USP standards.
• 25:00One-year production results: 124 batches, average yield 70%, 800 PET/CT scans.
• 30:00Challenges faced: design flaws, lack of local expertise, and regulatory issues.
• 35:00Future plans: expand to sodium fluoride, obtain GMP certification, and increase capacity.
• 40:00Q&A session discussing key strategies and advice for other centers.

• GE Healthcare MINItrace cyclotron — Mentioned as the cyclotron model used for isotope production.
• GE FASTlab synthesizer — Mentioned as the automated synthesizer for FDG production.
• United States Pharmacopeia (USP) — Referenced as the standard for quality control tests.
• International Atomic Energy Agency (IAEA) — Referenced for facility design recommendations and training.

• IAEA guidelines for cyclotron facilities — Provides general guidance on cyclotron facility design and safety, consistent with the presentation's emphasis on following IAEA recommendations.
• GMP for radiopharmaceuticals — Supports the presentation's discussion on GMP compliance for radiopharmaceutical production.

• None — No discordant sources were identified within the presentation.